Multidrug-Resistant Tuberculosis Drugs

Uses

Risks & contraindications

Evidence quality

Highlighted claims

• The included case reports were most numerous for bedaquiline and least numerous for pretomanid. — Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database
• The study evaluated real-world adverse event reports for bedaquiline, delamanid, and pretomanid using FAERS data from 2015 through 2023. — Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database
• Bedaquiline, delamanid, and pretomanid are central novel agents in current MDR-TB therapy. — Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database
• A positive adverse event signal required confirmation by all four disproportionality algorithms. — Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database
• All three drugs were associated with serious adverse event outcomes in more than half of reported outcomes. — Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database